| pubmed-article:2407336 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2407336 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:2407336 | lifeskim:mentions | umls-concept:C0019829 | lld:lifeskim |
| pubmed-article:2407336 | lifeskim:mentions | umls-concept:C0441766 | lld:lifeskim |
| pubmed-article:2407336 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2407336 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2407336 | pubmed:dateCreated | 1990-4-4 | lld:pubmed |
| pubmed-article:2407336 | pubmed:abstractText | A total of 228 previously untreated and eligible children with pathologic Stage I or II Hodgkin's disease were registered in the Intergroup Study of Hodgkin's Disease in Children between February 1977 and April 1981. Patients were randomized in the Southwest Oncology Group (later the Pediatric Oncology Group [POG] to involved-field (IF) radiotherapy alone or IF radiotherapy followed by six courses of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP) chemotherapy; patients in the Children's Cancer Study Group (CCSG) and Cancer and Leukemia Group B (CALGB) were randomized to receive extended-field (EF) radiotherapy or IF radiotherapy followed by six courses of MOPP. An estimated 97% of patients receiving IF + MOPP were relapse-free and surviving (RFS) at 5 years, which was significantly better than 41% for patients receiving IF alone; however there was essentially no overall difference in survival experience between groups. Patients in CCSG and CALGB receiving IF + MOPP had significantly superior RFS at 5 years than patients receiving EF. Survival rate was not different between these two groups, an estimated 93% of patients surviving 5 years or longer. Although patients were not randomized between IF or EF radiotherapy, they were similar with respect to patient characteristics. There was some statistical evidence that RFS was superior at 5 years for patients receiving EF than for IF; however, there was no evidence of a difference in survival experience. The percentages of patients with late effects of therapy were not significantly different by treatment. The most common types of late effects were endocrine dysfunction and impaired resistance to infection. Overall, the response rate to therapy for relapse patients was good, being 83% among all patients who relapsed. Patient characteristics related to poor prognosis were the presence of constitutional (B) symptoms (fever, night sweats, and weight loss) and poor performance status. | lld:pubmed |
| pubmed-article:2407336 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2407336 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2407336 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2407336 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2407336 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2407336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2407336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2407336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2407336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2407336 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2407336 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:2407336 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:GilchristG... | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:JohnstonJJ | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:GehanE AEA | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:SullivanM PMP | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:KennedyPP | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:FullerL MLM | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:FryerCC | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:HaysD MDM | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:HellerRR | lld:pubmed |
| pubmed-article:2407336 | pubmed:author | pubmed-author:HansonWW | lld:pubmed |
| pubmed-article:2407336 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2407336 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2407336 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:2407336 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2407336 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2407336 | pubmed:pagination | 1429-37 | lld:pubmed |
| pubmed-article:2407336 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:meshHeading | pubmed-meshheading:2407336-... | lld:pubmed |
| pubmed-article:2407336 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2407336 | pubmed:articleTitle | The intergroup Hodgkin's disease in children. A study of stages I and II. | lld:pubmed |
| pubmed-article:2407336 | pubmed:affiliation | Pediatric Intergroup Statistical Center, Houston, Texas. | lld:pubmed |
| pubmed-article:2407336 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2407336 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2407336 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2407336 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
